XML 120 R24.htm IDEA: XBRL DOCUMENT
v3.19.3.a.u2

Employee Benefits | 12 Months Ended
--- | ---
Dec. 31, 2019
Share-based Payment Arrangement, Noncash Expense [Abstract] |
Employee Benefits | EMPLOYEE BENEFITS We provide share-based compensation in the form of various types of equity-based awards, including restricted stock units (RSUs), performance share awards or units (PSUs) and stock options. Compensation expense is recognized on the Consolidated Statements of Income based on the estimated fair value of the award on the grant date. The estimated fair value of RSUs is based on the closing price of our common stock. For PSUs, estimated fair value is based on either the Monte Carlo valuation methodology or the stock price on the date of grant. For stock option awards, estimated fair value is based on the Black-Scholes option valuation model. 2004 Equity Incentive Plan In May 2004, our stockholders approved and we adopted the Gilead Sciences, Inc. 2004 Equity Incentive Plan (as amended, the 2004 Plan). The 2004 Plan is a broad based incentive plan that provides for the grant of equity-based awards, including stock options, restricted stock units, restricted stock awards and performance share awards, to employees, directors and consultants. The 2004 Plan authorized the issuance of a total of 309 million shares of common stock. As of December 31, 2019, a total of 79 million shares remain available for future grant under the 2004 Plan. Stock Options The 2004 Plan provides for option grants designated as either non-qualified or incentive stock options. All stock options granted after January 1, 2006 have been non-qualified stock options. Employee stock options generally vest over three or four years. All options are exercisable over a period not to exceed the contractual term of ten years from the date the stock options are issued and are granted at prices not less than the fair market value of our common stock on the grant date. Stock option exercises are settled with common stock from the 2004 Plan’s previously authorized and available pool of shares. The following table summarizes activity and related information under our stock option plans. All option grants presented in the table had exercise prices not less than the fair value of the underlying common stock on the grant date:
|  | Shares (in millions) |  | Weighted- Average Exercise Price (in dollars) |  | Weighted-Average Remaining Contractual Term (years) |  | Aggregate Intrinsic Value (in millions)
Outstanding at December 31, 2018 |  | 23.5 |  |  | $ | 53.80 |  |  |  |  |
Granted |  | 2.8 |  |  | $ | 65.87 |  |  |  |  |
Forfeited |  | (1.5 | ) |  | $ | 69.70 |  |  |  |  |
Expired |  | (0.4 | ) |  | $ | 75.64 |  |  |  |  |
Exercised |  | (4.9 | ) |  | $ | 24.06 |  |  |  |  |
Outstanding at December 31, 2019 |  | 19.5 |  |  | $ | 61.35 |  |  | 5.11 |  | $ | 238 |
Exercisable at December 31, 2019 |  | 14.3 |  |  | $ | 58.74 |  |  | 4.03 |  | $ | 224 |
Expected to vest, net of estimated forfeitures at December 31, 2019 |  | 4.9 |  |  | $ | 68.51 |  |  | 8.08 |  | $ | 13 |
Aggregate intrinsic value represents the value of our closing stock price on the last trading day of the year in excess of the weighted-average exercise price multiplied by the number of options outstanding or exercisable. Total intrinsic value of options exercised was $209 million for 2019, $412 million for 2018 and $337 million for 2017. The weighted-average grant date fair value of the stock options granted was $12.15 per share for 2019, $17.03 per share for 2018 and $38.78 per share for 2017. The weighted-average grant date fair value of stock options granted in 2017 was higher due to replacement awards granted in connection with our acquisitions of Kite and Cell Design Labs. As of December 31, 2019, there was $85 million of unrecognized compensation cost related to stock options, which is expected to be recognized over an estimated weighted-average period of 2.1 years. Restricted Stock and Performance Share Awards We grant time-based RSUs to certain employees as part of our annual employee equity compensation review program as well as to new hire employees and to non-employee members of our Board. RSUs are share-based awards that entitle the holder to receive freely tradable shares of our common stock upon vesting. RSUs generally vest over three or four years from the date of grant. The fair value of an RSU is equal to the closing price of our common stock on the grant date. We grant PSUs which vest upon the achievement of specified market or performance goals, which could include achieving a total shareholder return compared to a pre-determined peer group or achieving revenue targets. The actual number of common shares ultimately issued is calculated by multiplying the number of PSUs by a payout percentage ranging from 0% to 200%, and these awards generally vest only when a committee (or subcommittee) of our Board has determined that the specified market and performance goals have been achieved. The fair value of each PSU is estimated at the date of grant or when performance objectives are defined for the grants. Depending on the terms of the award, fair value on the date of grant is determined based on either the Monte Carlo valuation methodology or the closing stock price on the date of grant. In addition, we have also granted other PSUs to certain of our employees under the 2004 Plan. The vesting of these awards is subject to the achievement of specified individual performance goals, typically within a one to two year period. The fair value of such an award is equal to the closing price of our common stock on the grant date. The following table summarizes our RSU and PSU activity and related information (in millions, except per share amounts):
|  | RSUs |  | PSUs
|  | Shares |  | Weighted- Average Grant Date Fair Value Per Share |  | Shares (1) |  | Weighted- Average Grant Date Fair Value Per Share(1)
Outstanding at December 31, 2018 |  | 14.9 |  |  | $ | 77.72 |  |  | 0.8 |  |  | $ | 82.42 |
Granted |  | 9.6 |  |  | $ | 64.31 |  |  | 0.5 |  |  | $ | 68.30 |
Vested |  | (5.3 | ) |  | $ | 79.98 |  |  | (0.3 | ) |  | $ | 77.37 |
Forfeited |  | (2.0 | ) |  | $ | 72.89 |  |  | (0.3 | ) |  | $ | 69.25 |
Outstanding at December 31, 2019 |  | 17.2 |  |  | $ | 70.08 |  |  | 0.7 |  |  | $ | 80.42 |
_________________________________________ |  |  |  |  |  |  |  |
(1) | Weighted-average grant-date fair value per share excludes shares related to grants that currently have no grant date as the performance objectives have not yet been defined.
The weighted-average grant date fair value of RSUs granted was $64.31 per share for 2019, $77.98 per share for 2018, and $73.56 per share for 2017. The weighted-average grant date fair value of PSUs granted was $68.30 per share for 2019, $88.76 per share for 2018, and $74.42 per share for 2017. The total grant date fair value of our vested RSUs and PSUs was $450 million for , $481 million for 2018 and $329 million for 2017, and total fair value as of the respective vesting dates was $372 million for 2019, $446 million for 2018 and $288 million for 2017. As of December 31, 2019, there was $802 million of unrecognized compensation cost related to unvested RSUs and PSUs, which is expected to be recognized over a weighted-average period of 2.2 years. Employee Stock Purchase Plan Under our Employee Stock Purchase Plan and the International Employee Stock Purchase Plan (together, as amended, the ESPP), employees can purchase shares of our common stock based on a percentage of their compensation subject to certain limits. The purchase price per share is equal to the lower of 85% of the fair market value of our common stock on the offering date or the purchase date. The ESPP offers a six-month look-back feature as well as an automatic reset feature that provides for an offering period to be reset to a new lower-priced offering if the offering price of the new offering period is less than that of the current offering period. ESPP purchases are settled with common stock from the ESPP’s previously authorized and available pool of shares. During 2019, 2 million shares were issued under the ESPP for $90 million. A total of 79 million shares of common stock have been authorized for issuance under the ESPP, and there were 9 million shares available for issuance under the ESPP as of December 31, 2019. Stock-Based Compensation The following table summarizes total stock-based compensation expenses included on our Consolidated Statements of Income (in millions):
|  | Year Ended December 31,
|  | 2019 |  | 2018 |  | 2017
Cost of goods sold |  | $ | 48 |  |  | $ | 61 |  |  | $ | 24 |
Research and development expenses |  | 289 |  |  | 379 |  |  | 232 |
Selling, general and administrative expenses |  | 299 |  |  | 405 |  |  | 393 |
Stock-based compensation expense included in total costs and expenses |  | 636 |  |  | 845 |  |  | 649 |
Income tax effect(1) |  | 2 |  |  | (164 | ) |  | (280 | )
Stock-based compensation expense, net of tax |  | $ | 638 |  |  | $ | 681 |  |  | $ | 369 |
_______________________ |  |  |  |  |  |
(1) | Income tax effect for the year ended December 31, 2019 included a $114 million income tax expense following the U.S. Court of Appeals decision in Altera Corp v. Commissioner, which requires related parties in an intercompany cost sharing arrangement to share expenses related to stock-based compensation. See 19. Income Taxes, for additional information.
Stock-based compensation is recognized as expense over the requisite service periods on our Consolidated Statements of Income using the straight-line expense attribution approach, reduced for estimated forfeitures. We estimate forfeitures based on our historical experience. The requisite service period could be shorter than the vesting period if an employee is retirement eligible. Valuation Assumptions Fair value of options granted under our 2004 Plan and purchases under our ESPP were estimated at grant or purchase dates using a Black-Scholes option valuation model. The Black-Scholes option valuation model was developed for use in estimating the fair value of traded options, which have no vesting restrictions and are fully transferable. In addition, option valuation models require the input of highly subjective assumptions, including expected stock price volatility and expected award life. We used the following assumptions to calculate the estimated fair value of the awards:
|  | Year Ended December 31,
|  | 2019 |  | 2018 |  | 2017
Expected volatility: |  |  |  |  |  |
Stock options |  | 27 | % |  | 28 | % |  | 28 | %
ESPP |  | 27 | % |  | 28 | % |  | 28 | %
Expected term in years: |  |  |  |  |  |  |  |  |
Stock options |  | 5.5 |  |  | 5.2 |  |  | 4.6 |
ESPP |  | 0.5 |  |  | 0.5 |  |  | 0.5 |
Risk-free interest rate: |  |  |  |  |  |  |  |  |
Stock options |  | 2.3 | % |  | 2.5 | % |  | 2.1 | %
ESPP |  | 1.8 | % |  | 2.6 | % |  | 1.8 | %
Expected dividend yield |  | 3.6 | % |  | 2.8 | % |  | 2.7 | %
The fair value of stock options granted was calculated using the single option approach. We use a blend of historical volatility along with implied volatility for traded options on our common stock to determine our expected volatility. The expected term of stock-based awards represents the weighted-average period the awards are expected to remain outstanding. We estimate the weighted-average expected term based on historical cancellation and historical exercise data related to our stock options as well as the contractual term and vesting terms of the awards. The risk-free interest rate is based upon observed interest rates appropriate for the term of the stock-based awards. The dividend yield is based on our history and expectation of dividend payouts. Deferred Compensation We maintain a retirement saving plan under which eligible U.S. employees may defer compensation for income tax purposes under Section 401(k) of the Internal Revenue Code (the Gilead Sciences 401k Plan). In certain foreign subsidiaries, we maintain defined benefit plans as required by local regulatory requirements. Our total matching contribution expense under the Gilead Sciences 401k Plan and other defined benefit plans was $110 million during 2019, $91 million during 2018 and $74 million during 2017. We maintain a deferred compensation plan under which our directors and key employees may defer compensation. Amounts deferred by participants are deposited into a rabbi trust. The total assets and liabilities associated with the deferred compensation plan were $171 million as of December 31, 2019 and $124 million as of December 31, 2018.

X
- Definition The entire disclosure for share-based payment arrangement. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -URI http://asc.fasb.org/topic&trid=2228938 + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_ShareBasedCompensationAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration